Samsung BioLogics Co Ltd 207940
News
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
Samsung Biologics Reports Third Quarter 2026 Financial Results
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Samsung Biologics Seeks to Raise Over $2 Billion to Fund PolyPeptide Deal, Expansion — Update
Samsung Biologics to Buy PolyPeptide Group for About $2 Billion
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics Offers to Buy PolyPeptide for Around $1.8 Billion
Samsung Biologics Boosts U.S. Presence With $280 Million GSK Facility Deal

